120 related articles for article (PubMed ID: 30076850)
1. SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells.
Liu X; Han X; Wan X; He C; Wang Y; Mao A; Yu F; Zhou T; Feng L; Zhang P; Jin J; Ma X
Biochem Pharmacol; 2018 Oct; 156():43-51. PubMed ID: 30076850
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer.
Wang LT; Chiou SS; Chai CY; Hsi E; Chiang CM; Huang SK; Wang SN; Yokoyama KK; Hsu SH
Oncogene; 2017 Aug; 36(31):4405-4414. PubMed ID: 28368406
[TBL] [Abstract][Full Text] [Related]
3. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.
Li QQ; Xu JD; Wang WJ; Cao XX; Chen Q; Tang F; Chen ZQ; Liu XP; Xu ZD
Clin Cancer Res; 2009 Apr; 15(8):2657-65. PubMed ID: 19336515
[TBL] [Abstract][Full Text] [Related]
4. TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.
Wang LT; Wang SN; Chiou SS; Liu KY; Chai CY; Chiang CM; Huang SK; Yokoyama KK; Hsu SH
Oncogene; 2019 Jan; 38(4):518-532. PubMed ID: 30154425
[TBL] [Abstract][Full Text] [Related]
5. SPZ1 promotes deregulation of Bim to boost apoptosis resistance in colorectal cancer.
Liu XY; Zheng CB; Wang T; Xu J; Zhang M; Gou LS; Jin L; Qi X; Zeng X; Li H; Qiu S; Zhang P
Clin Sci (Lond); 2020 Jan; 134(2):155-167. PubMed ID: 31934723
[TBL] [Abstract][Full Text] [Related]
6. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.
Cheng GZ; Chan J; Wang Q; Zhang W; Sun CD; Wang LH
Cancer Res; 2007 Mar; 67(5):1979-87. PubMed ID: 17332325
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.
Khan MA; Tania M; Wei C; Mei Z; Fu S; Cheng J; Xu J; Fu J
Oncotarget; 2015 Aug; 6(23):19580-91. PubMed ID: 26023736
[TBL] [Abstract][Full Text] [Related]
8. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
10. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
Lee HJ; Li CF; Ruan D; Powers S; Thompson PA; Frohman MA; Chan CH
Mol Cell; 2016 Sep; 63(6):1021-33. PubMed ID: 27618486
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
12. bHLH-zip transcription factor Spz1 mediates mitogen-activated protein kinase cell proliferation, transformation, and tumorigenesis.
Hsu SH; Hsieh-Li HM; Huang HY; Huang PH; Li H
Cancer Res; 2005 May; 65(10):4041-50. PubMed ID: 15899793
[TBL] [Abstract][Full Text] [Related]
13. Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein.
Wei C; Cheng J; Zhou B; Zhu L; Khan MA; He T; Zhou S; He J; Lu X; Chen H; Zhang D; Zhao Y; Fu J
Sci Rep; 2016 Jul; 6():29822. PubMed ID: 27412325
[TBL] [Abstract][Full Text] [Related]
14. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
Chen J; Yuan W; Wu L; Tang Q; Xia Q; Ji J; Liu Z; Ma Z; Zhou Z; Cheng Y; Shu X
Oncotarget; 2017 Feb; 8(6):9961-9973. PubMed ID: 28035069
[TBL] [Abstract][Full Text] [Related]
15. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
[TBL] [Abstract][Full Text] [Related]
16. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
17. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
18. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein.
Chen Y; Li L; Zeng J; Wu K; Zhou J; Guo P; Zhang D; Xue Y; Liang L; Wang X; Chang LS; He D
Chemotherapy; 2012; 58(4):264-72. PubMed ID: 22986993
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
[TBL] [Abstract][Full Text] [Related]
20. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
